655 Madison Avenue
Suite 1900
New York, NY 10065
United States
844 845 7291
https://www.tilray.com
Settore/i: Healthcare
Settore: Drug Manufacturers—Specialty & Generic
Impiegati a tempo pieno: 1.700
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Irwin David Simon | Pres, CEO & Chairman | 13,68M | N/D | 1958 |
Mr. Carl A. Merton CA, CBV, CPA | CFO & Principal Accounting Officer | 1,13M | 98,24k | 1971 |
Mr. James R. Meiers | Chief Operations Officer | 1,2M | N/D | 1958 |
Ms. Denise Menikheim Faltischek | Chief Strategy Officer & Head of International | 1,19M | N/D | 1973 |
Mr. Lloyd Brathwaite | Chief Information Officer | N/D | N/D | N/D |
Mr. Roger Savell | Chief Admin. Officer | N/D | N/D | N/D |
Mr. John B. Sadler | VP of Investor Relations | N/D | N/D | N/D |
Ms. Dara Redler | Interim Chief Legal Officer & Corp. Sec. | N/D | N/D | N/D |
Mr. Mitch Gendell | Global Gen. Counsel & Corp. Sec. | N/D | N/D | N/D |
Mr. Bernard Yeung | Sr. VP of Sales & Marketing | N/D | N/D | N/D |
Tilray Brands Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. It operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. The company provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. It offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. The company operates Tilray Medical, a medical platform that provides GMP-certified flowers, oils, vapes, edibles, and topicals. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Tilray, Inc. Tilray Brands Inc. was incorporated in 2018 and is headquartered in New York, New York.
L'ISS Governance QualityScore di Tilray Brands, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.